
Transitioning from Compounded to Brand-Name GLP-1 Medications
On April 30, 2026, the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This wasn’t a sudden move. Novo Nordisk and Eli Lilly had already begun legal action against major 503B facilities months earlier, and…


